FrancophonIA/ELRC3.0 huggingface dataset:
English: Contraindications to lidocaine must be excluded before intramuscular injection of ceftriaxone when lidocaine solution is used as a solvent (see section 4.4).
Maltese: Kontraindikazzjoni għal lidocaine għandha tiġi eskluża qabel injezzjoni ġol-muskoli ta' ceftriaxone meta soluzzjoni ta' lidocaine tintuża bħala solvent (ara sezzjoni 4.4). Ara l-informazzjoni fis
English: In patients requiring continuous infusion with calcium-containing total parenteral nutrition (TPN) solutions, healthcare professionals may wish to consider the use of alternative antibacterial treatments which do not carry a similar risk of precipitation.
Maltese: F'pazjenti li jeħtieġu infużjoni kontinwa ta' soluzzjonijiet ta' nutrizzjoni parenterali totali (TPN - total parenteral nutrition) li fihom il-kalċju, professjonisti fil-kura tas-saħħa jistgħu jikkunsidraw l-użu ta' kura antibatterika alternattiva li m'għandhiex riskju simili ta' preċipitazzjoni.
English: The dose depends on the severity, susceptibility, site and type of infection and on the age and hepato-renal function of the patient.
Maltese: Id-doża tiddependi fuq is-severità, suxxettibilità, sit u tip ta' infezzjoni u fuq l-età u l-funzjoni renali u epatika tal-pazjent.
English: * In vitro studies have shown that ceftriaxone can displace bilirubin from its serum albumin binding sites leading to a possible risk of bilirubin encephalopathy in these patients.
Maltese: * Studji in vitro wrew li ceftriaxone jista' jieħu post il-bilirubina mis-siti fejn jeħel mal albumina fis-serum u jwassal għal riskju possibbli ta' enċefalopatija kkawżata minn bilirubina f'dawn il-pazjenti.
English: Contraindications to lidocaine, warnings and other relevant information as detailed in the Summary of Product Characteristics of lidocaine must be considered before use (see section 4.3).
Maltese: Kontraindikazzjonijiet għal lidocaine, twissijiet u informazzjoni rilevanti oħra kif dettaljati fil-Sommarju tal-Karatteristiċi tal-Prodott ta' lidocaine għandhom jiġu kkunsidrati qabel l-użu (ara sezzjoni 4.3).
English: Children
Maltese: Reżistenti
English: Rocephin is contraindicated in premature and full-term neonates at risk of developing bilirubin encephalopathy (see section 4.3).
Maltese: Rocephin huwa kontraindikat fi trabi tat-twelid prematuri u li twieldu meta kien imisshom li għandhom riskju li jiżviluppaw enċefalopatija kkawżata minn bilirubina (ara sezzjoni 4.3).
English: Acute otitis media
Maltese: Otite medja akuta
English: • 50-80 mg Rocephin for each kg of the child's body weight once a day depending on the severity and type of infection.
Maltese: 50 kg: • 50-80 mg ta' Rocephin għal kull kg ta' piż tal-ġisem tat-tifel/tifla darba kuljum skont is-severità u t-tip ta' infezzjoni.
English: • Rocephin may interfere with some types of blood glucose tests - please check with your doctor.
Maltese: • Rocephin jista' jinterferixxi ma' xi tipi ta' testijiet għall-glucose fid-demm - jekk jogħġbok iċċekkja mat-tabib tiegħek.
English: 1 g Powder for Solution for Injection or Infusion Ireland, Latvia, Malta, United Kingdom: Rocephin
Maltese: L-Irlanda, il-Latvja, Malta, ir-Renju Unit:
English: • Pain or a burning feeling along the vein where Rocephin has been given.
Maltese: • Għid lill-persuna li qed tieħu l-kampjun li inti ngħatajt Rocephin.
English: In symptomatic cases, conservative nonsurgical management is recommended and discontinuation of ceftriaxone treatment should be considered by the physician based on specific benefit risk assessment (see section 4.8).
Maltese: F'każijiet sintomatiċi, huwa rrakkomandat immaniġġjar mhux kirurġiku konservattiv u twaqqif tal-kura ta' ceftriaxone għandu jiġi kkunsidrat mit-tabib ibbażat fuq valutazzjoni speċifika tal-benefiċċju u r-riskju (ara sezzjoni 4.8).
English: If the use of ceftriaxone is considered necessary in patients requiring continuous nutrition, TPN solutions and ceftriaxone can be administered simultaneously, albeit via different infusion lines at different sites.
Maltese: Jekk l-użu ta' ceftriaxone huwa meqjus neċessarju f'pazjenti li jeħtieġu nutrizzjoni kontinwa, soluzzjonijiet ta' TPN u ceftriaxone jistgħu jingħataw fl-istess waqt, iżda permezz ta' linji tal-infużjoni differenti f'postijiet differenti.
English: See section 4.
Maltese: 10-14-il ġurnata.
English: ≤ 0.12c.
Maltese: J01DD04.
English: £ All methicillin-resistant staphylococci are resistant to ceftriaxone.
Maltese: L-istaphylococci kollha reżistenti għal methicillin huma reżistenti għal ceftriaxone.
English: For initial treatment of acute otitis media, a single intramuscular dose of Rocephin 50 mg/kg can be given.
Maltese: Għall-kura inizjali ta' otite medja akuta tista' tingħata doża waħda ġol-muskoli ta' Rocephin 50 mg/kg.
English: What Rocephin contains
Maltese: Rocephin jekk:
English: You have ever had problems with your gut, in particular colitis (inflammation of the bowel).
Maltese: Qatt kellek problemi fl-imsaren tiegħek, b'mod partikolari kolite (infjammazzjoni tal-musrana).
English: How to store Rocephin
Maltese: X'fih Rocephin
English: Appropriate fluid and electrolyte management should be instituted (see section 4.4).
Maltese: Għandu jiġi stabbilit immaniġġjar xieraq bi fluwidi u elettroliti (ara sezzjoni 4.4).
English: A single intramuscular dose of Rocephin 1-2 g can be given.
Maltese: 2 g darba kuljum għal 14-21 ġurnata.
English: Complicated urinary tract infections (including pyelonephritis) Infections of bones and joints
Maltese: Infezzjonijiet ikkumplikati fl-apparat tal-awrina (inkluż pajelonefrite) Infezzjonijiet tal-għadam u l-ġogi
English: Ceftriaxone penetrates the meninges.
Maltese: ceftriaxone u dijuretiċi qawwija (eż. furosemide).
English: In patients with both severe renal and hepatic dysfunction, close clinical monitoring for safety and efficacy is advised.
Maltese: F'pazjenti li għandhom disfunzjoni severa renali kif ukoll epatika, hija rrakkomandata sorveljanza klinika mill-viċin għas-sigurtà u l-effikaċja.
English: If you have a severe infection, your doctor will give you a higher dose up to 100 mg for each kg of body weight to a maximum of 4 g once a day.
Maltese: Jekk għandek infezzjoni severa, it-tabib tiegħek se jagħtik doża ogħla sa 100 mg għal kull kg ta' piż tal-ġisem sa massimu ta' 4 g darba kuljum.
English: • Children with a body weight of 50 kg or more should be given the usual adult dose.
Maltese: • Tfal li għandhom piż tal-ġisem ta' 50 kg jew aktar għandhom jingħataw id-doża normali għall adulti.
English: Severe renal and hepatic insufficiency
Maltese: Pazjenti b'indeboliment renali jew epatiku
English: Gall bladder precipitationb
Maltese: GĦAMLA KWALITATTIVA
English: Oedema Chills
Maltese: Moraxella catarrhalis
English: Patients with severe hepatic and renal impairment
Maltese: Pazjenti b'indeboliment epatiku u renali sever
English: • Reduction in number of red blood cells (anaemia).
Maltese: • Tnaqqis fin-numru ta' ċelluli ħomor tad-demm (anemija).
English: It can be given:
Maltese: Jista' jingħata:
English: Precipitation of ceftriaxone calcium salt in the gallbladder has been observed, primarily in patients treated with doses higher than the recommended standard dose.
Maltese: Preċipitazzjoni tal-melħ ceftriaxone-kalċju fil-marrara kienet osservata, primarjament f'pazjenti kkurati b'dożi ogħla mid-doża standard irrakkomandata.
English: The doctor will consider the benefit of treating you with Rocephin against the risk to your baby.
Maltese: It-tabib se jikkunsidra l-benefiċċju li jikkurak b'Rocephin kontra r-riskju għat-tarbija tiegħek.
English: Ceftriaxone is excreted into human milk in low concentrations but at therapeutic doses of ceftriaxone no effects on the breastfed infants are anticipated.
Maltese: Ceftriaxone huwa eliminat fil-ħalib tas-sider tal-bniedem f'konċentrazzjonijiet baxxi iżda b'dożi terapewtiċi ta' ceftriaxone mhux mistennija effetti fuq trabi li qegћdin jiġu mreddgћin.
English: Such precipitates disappear after discontinuation of ceftriaxone therapy.
Maltese: Għoti fl-istess waqt ta' probenecid ma jnaqqasx l-eliminazzjoni ta' ceftriaxone.
English: In polymicrobial infections, where suspected pathogens include organisms resistant to ceftriaxone, administration of an additional antibiotic should be considered.
Maltese: F'infezzjonijiet b'aktar minn mikrobu wieħed, fejn il-patoġeni suspettati jinkludu organiżmi reżistenti għal ceftriaxone, għandu jiġi kkunsidrat l-għoti ta' antibijotiku addizzjonali.
English: The dose recommendations in syphilis, including neurosyphilis, are based on limited data.
Maltese: Ir-rakkomandazzjonijiet tad-doża f'sifilide, inkluż newrosifilide, huma bbażati fuq dejta limitata.
English: Viridans group Streptococci Haemophilus influenzae
Maltese: Borrelia burgdorferi Haemophilus influenzae Haemophilus parainfluenzae Moraxella catarrhalis
English: History of severe hypersensitivity (e.g. anaphylactic reaction) to any other type of beta-lactam antibacterial agent (penicillins, monobactams and carbapenems).
Maltese: sustanza antibatterika beta-lactam (penicillins, monobactams u carbapenems). Ceftriaxone huwa kontraindikat fi:
English: Intravenous doses of 50 mg/kg or more in infants and children up to 12 years of age should be given by infusion.
Maltese: Dożi fil-vini ta' 50 mg/kg jew aktar fi trabi u tfal b'età sa 12-il sena għandhom jingħataw permezz ta' infużjoni.
English: Eosinophilia Leucopenia Thrombocytopenia
Maltese: Jekk tinsa tuża Rocephin
English: • Fungal infections (for example, thrush).
Maltese: • Infezzjonijiet ikkawżati mill-moffa (pereżempju, traxx).
English: Cases of renal precipitation have been reported, primarily in children older than 3 years of age and who have been treated with either high daily doses (e.g. ≥ 80 mg/kg/day) or total doses exceeding 10 grams and who presented with other risk factors (e.g. fluid restrictions or confinement to bed).
Maltese: Kienu rrappurtati każijiet ta' preċipitazzjoni fil-kliewi, primarjament fi tfal ta' età akbar minn 3 snin u li kienu kkurati b'dożi għoljin ta' kuljum (eż. ≥ 80 mg/kg/kuljum) jew b'dożi totali ta' aktar minn 10 grammi u li kellhom fatturi ta' riskju oħra (eż. restrizzjonijiet ta' fluwidi jew iżolament fis-sodda).
English: EMA/776490/2015 EMEA/H/C/003986
Maltese: EMEA/479129/2015 EMA/H/C/003986
English: Praxbind idarucizumab
Maltese: Informazzjoni oħra dwar Praxbind
English: The full EPAR and risk management plan summary for Praxbind can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Maltese: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: Praxbind has been investigated in three main studies involving 141 healthy adults who previously received dabigatran.
Maltese: Praxbind ġie investigat fi tliet studji ewlenin li involvew 141 adult b'saħħtu li kienu ngħataw qabel dabigatran.
English: This is a summary of the European public assessment report (EPAR) for Praxbind.
Maltese: Dan huwa sommarju tar-rapport pubbliku Ewropew ta' valutazzjoni (EPAR) għal Praxbind.
English: The active substance in Praxbind, idarucizumab, is a monoclonal antibody fragment.
Maltese: Is-sustanza attiva f'Praxbind, l-idarukizumab, hija framment ta' antikorp monoklonali.
English: Why is Praxbind approved?
Maltese: Għaliex ġie approvat Praxbind?
English: Results showed that Praxbind was able to completely neutralise Pradaxa's anticlotting effect within 5 minutes of use.
Maltese: Ir-riżultati wrew li Praxbind kien kapaċi jinnewtralizza kompletament l-effetti ta' kontra lkoagulazzjoni ta' Pradaxa fi żmien 5 minuti minn meta jintuża.
English: EPAR summary for the public
Maltese: Sommarju tal-EPAR għall-pubbliku idarukizumab
English: The main studies showed that Praxbind is effective at neutralising the effects of Pradaxa, and its action is rapid, complete and sustained.
Maltese: L-istudji ewlenin urew li Praxbind huwa effikaċi biex jinnewtralizza l-effetti ta' Pradaxa, u l-azzjoni tiegħu hija rapida, kompleta u sostnuta.
English: Praxbind is a medicine used to neutralise the effects of dabigatran (the active substance of Pradaxa), a medicine that treats and prevents blood clots.
Maltese: Praxbind huwa mediċina li tintuża biex tinnewtralizza l-effetti ta' dabigatran (is-sustanza attiva ta' Pradaxa), mediċina li tikkura u tipprevjeni l-emboli tad-demm.
English: What are the risks associated with Praxbind?
Maltese: X'inhuma r-riskji assoċjati ma' Praxbind?
English: Other information about Praxbind
Maltese: Kif jintuża Praxbind?
English: In the studies, volunteers received either Praxbind or placebo (a dummy treatment) after treatment with Pradaxa for 3.5 days.
Maltese: Fl-istudji, il-voluntiera rċevew Praxbind jew plaċebo (kura finta) wara kura bi Pradaxa għal 3.5 jiem.
English: In a still ongoing trial, an interim analysis showed similar results in 123 patients who had uncontrolled bleeding or required emergency surgery while using Pradaxa.
Maltese: Fi prova li għadha għaddejja, analiżi interim uriet riżultati simili f'123 pazjent li kellhom fsada mhux ikkontrollata jew kienu jeħtieġu operazzjoni ta' emerġenza waqt li kienu qegħdin jużaw Pradaxa.
English: Most patients in the study were taking Pradaxa to prevent stroke due to an ‘abnormal heart beat' (atrial fibrillation).
Maltese: Il-biċċa l-kbira tal-pazjenti fl-istudju kienu qegħdin jieħdu Pradaxa biex jipprevjenu puplesija minħabba "rata ta' taħbit tal-qalb mhux normali" (fibrillazzjoni atrijali).
English: A monoclonal antibody is a type of protein that has been designed to recognise and attach to a specific structure (called an antigen).
Maltese: Antikorp monoklonali huwa tip ta' proteina li tkun ġiet iddisinjata biex tagħraf u teħel ma' struttura speċifika (magħrufa bħala antiġen).
English: Praxbind is available as a solution for injection or infusion (drip) into a vein.
Maltese: Praxbind jiġi bħala soluzzjoni għall-injezzjoni jew infużjoni (dripp) ġol-vina.
English: A risk management plan has been developed to ensure that Praxbind is used as safely as possible.
Maltese: Ġie żviluppat pjan ta' ġestjoni tar-riskju biex jiġi żgurat li Praxbind jintuża bl-aktar mod sigur possibbli.
English: How is Praxbind used?
Maltese: Kif jaħdem Praxbind?
English: The recommended dose of Praxbind is 5 g given into a vein as two injections or infusions, one after the other.
Maltese: Id-doża rakkomandata ta' Praxbind hija 5 g mogħtija ġol-vina bħala żewġ injezzjonijiet jew infużjonijiet, waħda wara l-oħra.
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) therefore decided that Praxbind's benefits are greater than its risks and recommended that it be approved for use in the EU.
Maltese: Il-Kumitat għall-Prodotti Mediċinali għall-Użu mill-Bniedem (CHMP) għaldaqstant iddeċieda li l-benefiċċji ta' Praxbind huma akbar mir-riskji tiegħu u rrakkomanda li jkun approvat għall-użu fl-UE.
English: Further information on Delstrigo can be found on the Agency's website: ema.europa.eu/medicines/human/EPAR/delstrigo.
Maltese: ema.europa.eu/medicines/human/EPAR/delstrigo.
English: Delstrigo (doravirine / lamivudine / tenofovir disoproxil) EMA/873969/2018
Maltese: Delstrigo(doravirina / lamivudina / tenofovir disoproksil) EMA/661904/2018
English: Tenofovir is a nucleotide reverse transcriptase inhibitor.
Maltese: It-tenofovir hija inibitur nukleotidiku tat-transkriptażi inversa.
English: Delstrigo (doravirine / lamivudine / tenofovir disoproxil)
Maltese: Delstrigo(doravirina / lamivudina / tenofovir disoproksil)
English: Delstrigo is available as tablets, each containing doravirine 100 mg, lamivudine 300 mg and tenofovir disoproxil 245 mg.
Maltese: Delstrigo jiġi bħala pilloli, kull waħda fiha doravirina 100mg, lamivudina 300 mg u tenofovir disoproksil 245 mg.
English: In a study with 728 patients, 84% of patients treated with Delstrigo had undetectable levels of HIV in their blood (fewer than 40 copies/ml) after 48 weeks of treatment compared with 80% of patients given a combination of efavirenz, emtricitabine and tenofovir disoproxil.
Maltese: Fi studju b'728 pazjent, 84 % tal-pazjenti kkurati b'Delstrigo kellhom livelli ta' HIV li ma jistgħux jiġu osservati fid-demm tagħhom (inqas minn 40 kopja/ml) wara 48 ġimgħa ta' kura meta mqabbla ma' 80 % tal-pazjenti li ngħataw taħlita ta' efavirenz, emtriċitabina u tenofovir disoproksil.
English: Other information about Delstrigo
Maltese: Informazzjoni oħra dwar Delstrigo
English: Delstrigo is an antiviral medicine used to treat adults infected with human immunodeficiency virus type 1 (HIV-1), a virus that causes acquired immune deficiency syndrome (AIDS).
Maltese: Delstrigo huwa mediċina antivirali li tintuża fil-kura ta' adulti infettati bil-virus tal-immunodefiċjenza umana tat-tip 1 (HIV-1), virus li jikkawża s-sindromu tal-immunodefiċjenza akkwiżita (AIDS).
English: Delstrigo contains the active substances doravirine, lamivudine and tenofovir disoproxil.
Maltese: Delstrigo fih is-sustanzi attivi doravirina, lamivudina, u tenofovir disoproksil.
English: Delstrigo is as effective at keeping HIV infection under control as similar HIV combination treatments.
Maltese: Delstrigo huwa effettiv biex iżomm l-infezzjoni tal-HIV taħt kontroll daqs kuri ta' kombinazzjoni tal-HIV simili.
English: What are the risks associated with Delstrigo?
Maltese: X'inhuma r-riskji assoċjati ma' Delstrigo?
English: Doravirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) and lamivudine is a nucleoside reverse transcriptase inhibitor (NRTI).
Maltese: Id-doravirina hija inibitur mhux nukleosidiku tat-traskriptażi inversa (NNRTI) u llamivudina hija inibitur nukleosidiku tat-traskriptażi inversa (NRTI).
English: As for all medicines, data on the use of Delstrigo are continuously monitored.
Maltese: Bħal fil-każ tal-mediċini kollha, id-data dwar l-użu ta' Delstrigo hija ssorveljata kontinwament.
English: How is Delstrigo used?
Maltese: Delstrigo?
English: The three active substances in Delstrigo, doravirine, lamivudine and tenofovir disoproxil, block the activity of reverse transcriptase, an enzyme that allows HIV to reproduce itself in the cells it has infected.
Maltese: It-tliet sustanzi attivi f'Delstrigo, id-doravirina, il-lamivudina u t-tenofovir disoproksil jimblukkaw lattività tat-traskriptażi inversa, enzima li tippermetti l-HIV li tħalliha tipproduċi lilha nnifisha fiċ-ċelluli li tkun infettat.
English: The medicine is not suitable for patients who are infected with HIV that is resistant to lamivudine, tenofovir disoproxil or to medicines in the same class as doravirine (non-nucleoside reverse transcriptase inhibitors or NNRTIs).
Maltese: Il-mediċina mhijiex adattata għal pazjenti li huma infettati b'HIV li hija reżistenti għal-lamivudina, tenofovir disoproksil jew għal mediċini fl-istess klassi bħal dorvirina (inibituri mhux nukleosidiċi tat-traskriptażi inversa jew NNRTIs).
English: Tenofovir disoproxil is a ‘prodrug' of tenofovir, meaning that it is converted in the body to the active substance tenofovir.
Maltese: It-tenofovir disoproksil hija ‘promediċina' ta' tenofovir, li jfisser li tiġi kkonvertita fis-sustanza attiva tenofovir fil-ġisem.
English: Lamivudine and tenofovir disoproxil are already available in the European Union: lamivudine has been authorised since 1996 and tenofovir disoproxil since 2002.
Maltese: Il-lamivudina u t-tenofovir disoproksil huma diġà disponibbli fl-Unjoni Ewropea: il-lamivudina ilha awtorizzata mill-1996 u t-tenofovir disoproksil mill-2002.
English: Delstrigo was as effective at keeping HIV infection under control as a similar HIV combination treatment in a main study involving patients with HIV infection who had not been treated before.
Maltese: Delstrigo kien effettiv biex iżomm l-infezzjoni tal-HIV taħt kontroll bħala kura ta' kombinazzjoni tal-HIV simili fi studju ewlieni li kien jinvolvi pazjenti bl-infezzjoni tal-HIV li ma kinux ġew ikkurati qabel.
English: Side effects reported with Delstrigo are carefully evaluated and any necessary action taken to protect patients.
Maltese: L-effetti sekondarji rrappurtati b'Delstrigo huma evalwati bir-reqqa u kull azzjoni meħtieġa hi meħuda biex tipproteġi lill-pazjenti.
English: (Invented) name Strength Pharmaceutical Form Route of Administration Packaging
Maltese: Isem (ivvintat) Qawwa Għamla farmaċewtika
English: Italy: TIENAM (20 ml), IMIPEM (20 ml) and TENACID (20 ml) Latvia: TIENAM I.V.
Maltese: L-Italja: TIENAM (20 ml), IMIPEM (20 ml) and TENACID (20 ml) Il-Latvja:
English: Paediatric population ≥1 year of age
Maltese: Popolazzjoni pedjatrika età ≥1 sena
English: LIST OF EXCIPIENTS Sodium bicarbonate (E500)
Maltese: LISTA TA' SUSTANZI MHUX ATTIVI Sodium bicarbonate (E500)
English: Gram-negative aerobes:
Maltese: Aerobi Gram-negattivi:
English: 25 vials
Maltese: 25 kunjett
English: Biotransformation and elimination
Maltese: Biotrasformazzjoni u eliminazzjoni
English: Oral anti-coagulants
Maltese: Antikoagulanti orali
English: Gram-negative anaerobes: Bacteroides fragilis Bacteroides fragilis group Fusobacterium spp.
Maltese: Bacteroides fragilis Grupp Bacteroides fragilis Fusobacterium spp.
English: Interaction with valproic acid
Maltese: Interazzjoni ma' valproic acid
English: Stenotrophomonas maltophilia (formerly Xanthomonas maltophilia, formerly Pseudomonas maltophilia)
Maltese: Stenotrophomonas maltophilia (li qabel kienet Xanthomonas maltophilia, li qabel kienet Pseudomonas maltophilia)
English: Incompatibility
Maltese: Inkompatibbiltà
English: Very rare vertigo, tinnitus
Maltese: Rari ħafna vertiġini, tinnitus
English: Actual body weight (kg) X standard dose 70 (kg)
Maltese: Piż attwali tal-ġisem (kg) X doża standard 70 (kg)
English: dose in mg (interval hrs)
Maltese: doża f'mg (intervall sigħat)
English: The mean plasma half-lives of imipenem and cilastatin were 91 ± 7.0 minutes and 69 ± 15 minutes, respectively.
Maltese: Il- half-lives medji ta' imipenem u cilastatin filplażma kienu ta' 91 ± 7.0 minuti u 69 ± 15-il minuta, rispettivament.
English: System Organ Class
Maltese: Klassi tas-Sistema u talOrganu
English: Very rare aggravation of myasthenia gravis, headache
Maltese: Rari ħafna aggravvament ta' myasthenia gravis, uġigħ ta' ras
English: Germany: ZIENAM
Maltese: Il-Ġermanja: ZIENAM
English: Staphylococcus coagulase negative (Methicillin-susceptible) Streptococcus agalactiae
Maltese: Staphylococcus negattiv għall-coagulase (suxxettibbli għall-Methicillin) Streptococcus agalactiae
English: Rare toxic epidermal necrolysis, angioedema, Stevens-Johnson syndrome, erythema multiforme, exfoliative dermatitis
Maltese: Rari nekroliżi epidermali tossika, anġjoedima, sindrome ta' Stevens-Johnson, eritema multiforme, dermatite bil-ġilda taqa' qxur qxur
English: • Severe skin reactions (Stevens-Johnson syndrome and erythema multiforme)
Maltese: • Reazzjonijiet qawwija fil-ġilda (sindrome ta' Stevens-Johnson u eritema multiforme)
English: The total daily dose (i.e. 2000/2000, 3000/3000 or 4000/4000 mg) that would usually be applicable to patients with normal renal function should be selected.
Maltese: Għandha tintgħażel id-doża totali ta' kuljum (i.e. 2000/2000, 3000/3000 jew 4000/4000 mg) li normalment tkun tapplika għal pazjenti b'funzjoni tal-kliewi normali.
English: In clinical trials including 1,723 patients treated with imipenem/cilastatin intravenous the most frequently reported systemic adverse reactions that were reported at least possibly related to therapy were nausea (2.0%), diarrhoea (1.8%), vomiting (1.5%), rash (0.9%), fever (0.5%), hypotension (0.4%), seizures (0.4%) (see section 4.4), dizziness (0.3%), pruritus (0.3%), urticaria (0.2%), somnolence (0.2%).
Maltese: Fi provi kliniċi li kienu jinkludu 1,723 pazjent ikkurati b'imipenem/cilastatin għal ġol-vini l-aktar reazzjonijiet sistemiċi avversi rrappurtati b'mod frekwenti rrappurtati li mill-anqas hemm il-possibiltà li għandhom x'jaqsmu mal-kura kienu nawsja (2.0%), dijarea (1.8%), rimettar (1.5%), raxx (0.9%), deni (0.5%), pressjoni baxxa (0.4%), aċċessjonijiet (0.4%) (ara sezzjoni 4.4), sturdament (0.3%), ħakk (0.3%), urtikarja (0.2%), ħedla tan-ngħas (0.2%).
English: Central nervous system
Maltese: Sistema ċentrali nervuża
English: Streptococcus viridans group
Maltese: Grupp Streptococcus viridans
English: Common eosinophilia
Maltese: Komuni eosinofilja
English: • Reduced affinity of PBPs to imipenem
Maltese: • Tnaqqis fl-affinità ta' PBPs għal imipenem
English: France: TIENAM
Maltese: Franza: TIENAM